Sources

6 Total Sources

EyePoint, Stellantis and Enovix Sink to 52-Week Lows as 67% Plunge Leads Selloff

Left25%

Center50%

Far Right25%

Yahoo Finance2d ago

EYPT, STLA, ENVX Stocks Hit 52-Week Lows Amid Trial Failure, Recall, CEO Exit

Yahoo Finance3d ago

EyePoint Pharmaceuticals Shares Crash 70% After Duravyu Wet AMD Trial Failure

Investor's Business Daily3d ago

EyePoint (EYPT) Stock Crashes After Duravyu Fails Final-Phase Study Goal

EyePoint Pharmaceuticals Shares Plummet 70% After Duravyu Fails Phase 3 Trial

EyePoint's Phase 3 fail sends stock spiraling amid next-gen AMD race - BioSpace

Stocktwits3d ago

EYPT Stock On Track To Hit 16-Month Lows After Wet AMD Trial Setback – Retail Sees Ocular Therapeutics As A Better Buyout Candidate